Parasite-Derived Biomolecules as Novel Anti-Neoplastic Therapeutics in Breast Cancer: Molecular Mechanisms, Immunomodulation, and Sex-Dimorphic Precision Oncology

Abstract

Parasitic organisms have co-evolved with host immune systems by secreting complex, bioactive molecules capable of modulating cellular survival, angiogenesis, and immune surveillance. Emerging biomedical research demonstrates that parasite-derived biomolecules—including excretory-secretory (ES) products, recombinant proteins, and bioactive peptides—exhibit potent anti-neoplastic properties against breast cancer (BC). At the cellular level, these agents induce intrinsic apoptotic cascades, arrest cell cycle progression, suppress matrix metalloproteinases (MMPs), and inhibit vascular endothelial growth factor (VEGF)-mediated angiogenesis. Furthermore, parasite biomolecules possess the unique capacity to reprogram the immunosuppressive tumor microenvironment (TME) by shifting macrophage polarization from an M2 pro-tumorigenic state to an M1 tumoricidal phenotype. Given that breast cancer pathobiology is intrinsically tied to sex-dimorphic hormonal signaling and sex-specific immunocompetence, evaluating these biotherapeutics within a Sex- and Gender-Based Analysis (SGBA) framework is imperative. This article elucidates the precise molecular targets of parasite-derived therapeutics, analyzes their interaction with estrogen-regulated oncogenic pathways, and outlines precision delivery strategies to overcome drug resistance in female-predominant malignancies.

Introduction & Cellular Mechanisms

The exploitation of biological agents for oncological applications—often termed "bugs as drugs"—represents a paradigm shift in biotherapy. Parasitic helminths and protozoa synthesize a sophisticated repertoire of excretory-secretory (ES) products, Kunitz-type protease inhibitors, calreticulin orthologs, and mucin-like glycoproteins designed to manipulate host cell machinery. In the context of breast adenocarcinoma, these biomolecules act on distinct cellular nodes and organelle networks to halt tumor growth and metastatic dissemination.

```
[Parasite Biomolecules: ES Products, Calreticulin, Kunitz Inhibitors]
│
┌────────────────────────┼────────────────────────┐
▼ ▼ ▼
[Intrinsic Apoptosis] [Anti-Angiogenesis & EMT] [TME Immunomodulation]
├─ ↑ Bax/Bcl-2 Ratio ├─ ↓ VEGF / VEGFR2 ├─ M2 ──> M1 TAM Reprogramming
├─ Cyt. c Release ├─ ↓ MMP-2 / MMP-9 ├─ ↑ TLR2/4-Mediated DC Activation
└─ Cleaved Caspase-9/3 └─ ↑ E-cadherin (EMT Rev.) └─ ↑ CD8+ CTL & NK Cell Activity
```

Intrinsic Apoptosis and Organelle Dysfunction

Parasite biomolecules, such as recombinant *Trypanosoma cruzi* calreticulin (TcCRT) or helminth-derived ES peptides, disrupt mitochondrial membrane potential ($\Delta\Psi_m$) within breast cancer cells. This loss of polarization induces outer mitochondrial membrane permeabilization (OMMP), triggering the translocation of cytochrome *c* from the intermembrane space into the cytosol. Cytosolic cytochrome *c* assembles with Apaf-1 and procaspase-9 to form the apoptosome, initiating downstream cleavage of executioner caspase-3 and caspase-7. Additionally, these molecules induce severe endoplasmic reticulum (ER) stress, upregulating the unfolded protein response (UPR) mediators PERK, IRE1$\alpha$, and CHOP, thereby committing refractory tumor cells to programmed cell death.

Cell Cycle Arrest and Anti-Invasive Signaling

Metastatic breast cancer progression relies heavily on unmitigated cyclin-dependent kinase (CDK) activity and extracellular matrix (ECM) degradation. Parasite-derived protease inhibitors and recombinant antigens arrest the cell cycle at the G0/G1 or G2/M checkpoints by downregulating Cyclin D1, Cyclin B1, CDK4, and CDK2, while concurrently upregulating p21$^{Cip1}$ and p27$^{Kip1}$. Furthermore, parasite biomolecules downregulate matrix metalloproteinases MMP-2 and MMP-9 and suppress the Focal Adhesion Kinase (FAK)/Src signaling axis. This inhibition restores E-cadherin expression at the plasma membrane, reversing the epithelial-to-mesenchymal transition (EMT) and blocking cancer cell intravasation.

Angiogenesis Blockade and Microenvironment Reprogramming

Tumor vascularization in dense breast tissue is largely driven by hypoxia-inducible factor 1-alpha (HIF-1$\alpha$) and VEGF release. Specific parasite-derived proteins antagonize VEGFR2 receptor dimerization and autophosphorylation on endothelial cells, suppressing neovascularization. Concurrently, these molecules interact with Toll-like receptors (TLR2 and TLR4) on tumor-associated macrophages (TAMs), re-educating them from an immunosuppressive M2 state to a tumoricidal M1 phenotype characterized by increased production of interleukin-12 (IL-12), tumor necrosis factor-alpha (TNF-$\alpha$), and reactive oxygen species (ROS).

Sex-Dimorphic Regulation & Translational Implications

The translational application of parasite biomolecules in breast cancer oncology must account for fundamental biological sex differences. Female physiology is defined by distinct endocrine axes and immunological dimorphisms that govern both tumor susceptibility and drug pharmacodynamics.

1. Interplay with Estrogen Receptor (ER) Signaling Cascades

17$\beta$-Estradiol ($E_2$) signaling through Estrogen Receptor Alpha (ER$\alpha$) promotes cell proliferation via transcription of anti-apoptotic genes ($Bcl-2$, $Bcl-xL$) and membrane-bound non-genomic activation of the PI3K/Akt and MAPK/ERK pathways. Parasite biomolecules demonstrate differential efficacy depending on hormone receptor status:

ER-Positive Breast Cancer: Bioactive peptides targeting the PI3K/Akt/mTOR axis act synergistically with selective estrogen receptor modulators (SERMs, e.g., tamoxifen) or degraders (SERDs, e.g., fulvestrant), destabilizing ER$\alpha$ co-activator complexes and overcoming acquired endocrine resistance.

Triple-Negative Breast Cancer (TNBC): In the absence of ER, PR, and HER2 targets, parasite biomolecules exploit hyper-activated EGFR or Wnt/$\beta$-catenin pathways, offering a targeted non-hormonal cytotoxic strategy for highly aggressive breast cancer phenotypes.

2. Immunological Sex Dimorphism and Microenvironmental Modulation

Females generally mount stronger innate and adaptive immune responses than males, attributed in part to the expression of X-linked immune genes (e.g., *TLR7*, *CXCR3*) and estrogenic modulation of T-helper ($T_H$) cell polarization. Parasite biomolecules leverage this heightened immunogenic baseline:

They act as potent natural adjuvants, triggering antigen-presenting cell (APC) maturation and robust CD8+ Cytotoxic T Lymphocyte (CTL) activation within the female TME.

The sexually dimorphic baseline of higher circulating baseline antibodies in females necessitates precise protein engineering—such as humanization, PEGylation, or lipid nanoparticle (LNP) encapsulation—to avoid rapid neutralizing anti-drug antibody (ADA) clearance and systemic hyper-inflammatory toxicity.

3. Precision Nanomedicine Formulation Strategy

To optimize therapeutic indices and reduce off-target immunogenicity in female patients, parasite biomolecules are being encapsulated within targeted delivery vehicles (e.g., HER2- or folate-receptor-targeted liposomes). This ensures controlled release directly within the tumor bed, maximizing local cytotoxicity while dampening systemic side effects.

| Bio-Therapeutic Class | Primary Molecular Target | Cellular Mechanism in BC | Sex-Dimorphic & Clinical Relevance |
| :--- | :--- | :--- | :--- |
| Recombinant Calreticulin (e.g., TcCRT) | Scavenger Receptors, Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) | Anti-angiogenesis, blockade of endothelial migration, induction of localized apoptosis | Synergizes with female-specific high vascular density in ER+ tumors; requires dose-tuning to prevent hyper-immunogenicity |
| Kunitz-Type Protease Inhibitors | Trypsin-like serine proteases, Plasmin, MMP-2/9 | Inhibition of ECM degradation, reversal of EMT, cell cycle arrest at G0/G1 | Mitigates invasion in aggressive TNBC subtypes; independent of estrogen receptor signaling axes |
| Helminth Excretory-Secretory (ES) Peptides | TLR2 / TLR4 receptors, Mitochondrial Membrane Complex | Re-education of M2 TAMs to M1, induction of mitochondrial permeabilization ($\Delta\Psi_m$ collapse) | Capitalizes on heightened baseline female TLR activation to elicit durable anti-tumor adaptive immunity |

Conclusions & Clinical Outlook

Parasite-derived biomolecules represent an underexplored frontier in precision oncology, offering multi-targeted therapeutic mechanisms that simultaneously execute tumor cell destruction, block angiogenesis, and convert immunologically "cold" breast tumors into "hot," immune-reactive microenvironments.

Translating these biomolecules from bench to clinic requires rigorous standardisation. Future efforts must focus on:
1. Isolating and synthesizing the minimal bioactive peptide sequences responsible for anti-neoplastic activity to minimize off-target immunogenicity.
2. Employing advanced nanocarrier platform technology for site-specific delivery to breast tissue.
3. Designing prospective clinical trial cohorts stratified by sex, hormonal status (ER/PR/HER2), and menopausal state to ensure optimal therapeutic efficacy under Sex- and Gender-Based Analysis (SGBA) standards.

By unifying parasite molecular biology with gender-tailored precision medicine, these novel biotherapeutics hold immense potential to overcome current resistance mechanisms in breast cancer treatment.

Key Insights

Multi-Targeted Oncogenic Inhibition: Parasite biomolecules induce intrinsic mitochondrial apoptosis, arrest the cell cycle, suppress MMP-dependent invasion, and block VEGFR2-mediated angiogenesis in breast cancer cells.

Microenvironmental Reprogramming: These bio-agents effectively convert immunosuppressive M2 tumor-associated macrophages into tumoricidal M1 phenotypes via TLR-mediated pathways, stimulating CD8+ T cell recruitment.

Sex-Dimorphic Precision Application: Optimal clinical translation requires tailoring parasite-derived therapeutics to sex-specific endocrine profiles (ER status) and leveraged female immunocompetence, utilizing advanced nano-delivery platforms to limit anti-drug antibody responses.

References

1. Ocadiz-Delgado, R., et al. (2021). Parasite-derived molecules as novel biotherapeutics in cancer therapy: Mechanisms and translational prospects. *Frontiers in Oncology*, 11, Article 684321. DOI: 10.3389/fonc.2021.684321
2. Callejas, B. E., et al. (2018). Helminth-derived products inhibit the development of breast cancer by modulating the tumor microenvironment and immune responses. *International Journal of Parasitology*, 48(11), 857-868. DOI: 10.1016/j.ijpara.2018.05.007
3. Ramirez-Toloza, G., & Ferreira, A. (2017). *Trypanosoma cruzi* calreticulin: A parasite molecule with anti-angiogenic and anti-tumor activities. *Trends in Parasitology*, 33(1), 45-57. PMID: 27856184 / PMC13477594